Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Hinge Health in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Hinge Health’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:14 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054327
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Cost of revenue | 28,868 | 41,335 | 56,942 | 64,927 |
| Gross profit | 183,949 | 97,763 | 338,182 | 197,996 |
| Operating expenses: | ||||
| Research and development | 34,057 | 279,962 | 64,395 | 303,462 |
| Sales and marketing | 81,408 | 147,228 | 150,210 | 193,944 |
| General and administrative | 28,044 | 251,244 | 51,068 | 268,125 |
| Total operating expenses | 143,509 | 678,434 | 265,673 | 765,531 |
| Income (loss) from operations | 40,440 | (580,671) | 72,509 | (567,535) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Hinge Health's R&D?
- Hinge Health (HNGE) reported R&D of $34.06M in Q2 2026.
- How has Hinge Health's R&D changed year-over-year?
- Hinge Health's R&D decreased by 87.8% year-over-year, from $279.96M to $34.06M.
- What is the long-term trend for Hinge Health's R&D?
- Over 2 years (2023 to 2025), Hinge Health's R&D has grown at a 82.9% compound annual growth rate (CAGR), from $110.06M to $368.14M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Hinge Health's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude